An animal study by Morgentaler and Traish showed that beyond a certain serum testosterone concentration, androgens have a limited ability to stimulate prostate cancer growth . Long-term cessation of the prostate's exposure to androgen appears to protect against the development of cancer, but no dose-response relationship between testosterone level and cancer risk has been established. Odds ratios with 95% confidence intervals (CIs) for PSA, PSAD, serum testosterone, and age were determined to predict prostate cancer risk. For possible correlation between serum testosterone, PSA, and prostate cancer, we included age, PSA density (PSAD), prostate volume, and Gleason score for patients with prostate cancer. To determine the relationship between testosterone, PSA, and prostate cancer risk in a high-risk group, we limited our study population to men with a PSA level of 10 ng/ml or higher. Isbarn et al's recent studies, however, show a result opposite that of Huggins and Hodges, implying that testosterone neither increases the risk of prostate cancer nor causes cancer recurrence in men who have been treated successfully for prostate cancer . Binary logistic regression analysis of prostate cancer risk predictors Out of 120 patients, the samples of 85 (70.1%) patients were diagnosed as benign and those of 35 (29.2%) patients were diagnosed as being prostate cancer. Huggins and Hodges's seminal work in the 1940s first demonstrated the hormone dependence of prostate cancer , consequently establishing testosterone as a key therapeutic target for managing prostate cancer. Testosterone is essential for the normal growth and development of the prostate gland and is also a possible risk factor for prostate cancer 1,2. Testosterone replacement therapy (TRT) can help improve the symptoms of low testosterone due to male hypogonadism. The idea of the five lobes of the prostate was popularized following anatomical studies conducted by American urologist Oswald Lowsley in 1912. A monograph, "Practical observations on the treatment of the diseases of the prostate gland" by Everard Home in 1811, was important in the history of the prostate by describing and naming anatomical parts of the prostate, including the median lobe. Usually the procedure for cancer is a radical prostatectomy, which means that the seminal vesicles are removed and the vasa deferentia are also tied off. If a cancer is small and localised, the decision may be made to monitor for cancer activity at intervals ("active surveillance") and defer treatment. Those with PSA levels below average are very unlikely to develop dangerous prostate cancer over the next 8 to 10 years. This is done through blood tests to measure levels of the protein prostate-specific antigen (PSA), which are elevated in those with enlarged prostates, whether due to prostate cancer or benign prostatic hyperplasia. Elevated PSA levels can indicate prostate problems, including infection, inflammation, benign prostatic hyperplasia (BPH), and prostate cancer. The concern stems from the fact that testosterone can fuel the growth of existing prostate cancer cells. Because testosterone can fuel the growth of prostate cancer cells, it’s crucial to detect and treat any existing cancer before starting TRT. In our study's results, serum testosterone at the time of diagnosis was unrelated to PSA elevation, prostate cancer risk, and aggressiveness. This study's aim was to determine the significance of serum testosterone for prostate-specific antigen (PSA) elevation and prostate cancer prediction in high-risk men. To allow the therapy to take full effect, healthcare providers typically wait 30 days after you start TRT to check your testosterone levels. In 1941, Charles B. Huggins published studies in which he used estrogen to oppose testosterone production in men with metastatic prostate cancer. Because of the significant risk of overdiagnosis with widespread screening in the general population, prostate cancer screening is controversial.
